During its presentation at the 44th Annual J.P. Morgan Healthcare Conference, Teva Pharmaceutical Industries’ management outlined a series of strategic priorities and pipeline milestones scheduled for the next 12 to 18 months. CEO Kåre Schultz highlighted that the company expects three major launches in specialty neurology, including a novel multiple sclerosis therapy entering Phase III trials by Q3 2026. CFO Eyal Deshe emphasized a plan to reduce operating expenses by 8% year-over-year through supply-chain optimization and a global headcount realignment, targeting annual run-rate savings of $350 million by the end of 2025. The team reaffirmed its commitment to pay down $2.5 billion of debt within the next two years, leveraging improved cash flows from recent product approvals and generics growth in the U.S. market.

Teva’s management raised its mid-cycle revenue growth target to 4–6% through 2028, up from prior guidance of 3–5%, driven by expanding specialty portfolios and anticipated volume gains in key generic drugs. They forecast adjusted EBITDA margins improving to 32% by fiscal 2027, supported by productivity programs and the divestiture of non-core assets completed last quarter, which generated net proceeds of $450 million. Analysts noted that free cash flow is expected to exceed $2.8 billion in the current fiscal year, compared with $2.3 billion a year earlier, bolstering Teva’s capacity to fund R&D investments and return capital to shareholders. This set of forward-looking targets prompted a significant increase in buy ratings among three major sell-side firms.

Teva has entered into a $500 million non-dilutive funding agreement with Royalty Pharma to fast-track the development of its lead vitiligo candidate, TEV-408. Under the terms, Teva retains full global commercialization rights and will use the capital to advance the compound through late-stage clinical trials, with topline data expected in mid-2026. Royalty Pharma will receive tiered royalties on net sales, starting at low double digits, once TEV-408 reaches the market. This partnership offsets historical R&D spend of approximately $120 million on the program to date and allows Teva to preserve balance-sheet flexibility while securing external validation of its dermatology franchise potential.